Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell combo Stent vs. biolimus eluting absorbable polymer coated biomatrix alpha stent in patients undergoing percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for randomized trials with clinical outcome (SORT OUT) XI trial - 03/03/25
, Evald Høj Christiansen, MD PhD b, Jens Flensted Lassen, MD PhD c, d, Bent Raungaard, MD PhD a, Lars Jakobsen, MD PhD b, Lisette Okkels Jensen, MD DMSci PhD c, dABSTRACT |
Rationale |
The biodegradable polymer Biomatrix Alpha stent contains biolimus A9 drug which is a sirolimus derivative increased in lipophicity. The biodegradable polymer sirolimus eluting Combo stent is a dual-therapy sirolimus-eluting and CD34+ antibody coated stent capturing endothelial progenitor cells (EPCs).
Hypothesis |
The main hypothesis of the SORT OUT XI trial was that the biodegradable polymer biolimus A9 Biomatrix Alpha stent is noninferior to the biodegradable polymer sirolimus eluting Combo stent in an all-comers population with coronary artery disease undergoing percutaneous coronary intervention (PCI).
Methods |
The SORT OUT XI study was a randomized, multicenter, single blinded, all-comer, 2-arm, noninferiority trial comparing the biodegradable polymer biolimus A9 Biomatrix Alpha stent to the biodegradable polymer sirolimus eluting Combo stent in 3 Danish University Hospitals in Western Denmark. The composite primary endpoint was target lesion failure (TLF) within 12 months. TLF was defined as composite of cardiac death, myocardial infarction not related to other than index lesion or target lesion revascularization. Clinically driven event detection was used and no planned follow up was performed. With a sample size of 1,564 patients in each treatment arm, a 2-group large-sample normal approximation test of proportions with a 1-sided 5% significance level had a 90% power to detect noninferiority with a predetermined noninferiority margin of 2.1%.
Results |
The trial ran from August 14, 2019 to March 19, 2023. A total of 3141 patients were enrolled and randomized 1:1 to Combo stent (n = 1,573) and Biomatrix Alpha stent (n = 1,568).
Conclusion |
The SORT OUT XI trial will assess if the biolimus A9 eluting Biomatrix Alpha stent is noninferior to the dual-therapy Combo stent with respect to target lesion failure.
ClinicalTrials.gov |
NCT03952273.
Le texte complet de cet article est disponible en PDF.Plan
Vol 283
P. 37-42 - mai 2025 Retour au numéro
Article précédent
- Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease
- David E. Kandzari, Azeem Latib, Darren Mylotte, Ziad A. Ali, Azfar Zaman, Sandeep Brar, Maria Parke, Bruno Scheller
- Study protocol for the healthy family program on population blood pressure: A multicenter, parallel group, cluster randomized, controlled trial in rural China
- Yangyang Tang, Chao Jiang, Jiakun Guo, Yueyuan Li, Chi Wang, Shuk Han Chu, Zhiyan Wang, Yanfang Wu, Chang Hua, Yanmei Lu, Shuai Zhang, Yanna Song, Rong Han, Jianzeng Dong, Changsheng Ma, Jun Cai, Craig S. Anderson, Xin Du
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?